IMAX CORPORATION

IMAX

CIK 0000921582 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$121M
↑+91.5% +$58Mvs FY2024 (Q4)
Operating Income
$24M
↑+153.4% +$15Mvs FY2024 (Q4)
Net Income
$637K
↓-88.0% -$5Mvs FY2024 (Q4)
Gross Profit
$70M
↑+111.4% +$37Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Strong
65/100
  • Profitability
    70ROIC 19.0% (10% = solid, 20%+ = moat)
  • Liquidity
    0Insufficient data
  • Leverage
    100D/E 0.01 (under 0.5 = conservative)
  • Efficiency
    21Asset Turnover 0.48x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +91.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 19.9% · trend +6.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project IMAX's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 137.3%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$71.40
Total enterprise IV
$3.97B
Diluted shares
0.06B
Terminal PV
$3.08B (78% of total)
Year-5 FCF
$363M
YearProjected FCFDiscounted PV
+1$149M$135M
+2$186M$154M
+3$232M$174M
+4$290M$198M
+5$363M$225M
Terminal$4.96B$3.08B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$8M
investment in PP&E
Stock buybacks (TTM)
$0
share count reduction
Stock-based comp (TTM)
$27M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$894M
everything owned
Total liabilities
$466M
everything owed
Stockholders' equity
$338M
shareholder claim
Net debt
$-150M
Net cash position ($150M)

Recent performance · 64 quarters

Revenue↑+91.5% +$58M
$121M
Net Income↓-88.0% -$5M
$637K
Free Cash Flow↑+306.8% +$21M
$28M
Operating Margin↑+4.9pts
19.9%

Drill down